Arbutus Biopharma's three largest insider shareholders as of April 17, 2026 are Michael J. Mcelhaugh (Interim President Ceo, 1.66Mn shares), Michael J. Sofia (Chief Scientific Officer, 1.49Mn shares), William H. Collier (President And Ceo, 216.50K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Michael J. Mcelhaugh | Interim President Ceo | 1,658,003 | 0 | 19 Feb, 2025 |
| Michael J. Sofia | Chief Scientific Officer | 1,485,121 | 0 | 05 Feb, 2024 |
| William H. Collier | President And Ceo | 216,500 | 0 | 03 Feb, 2023 |
| Karen Sims | Chief Medical Officer | 155,494 | 0 | 19 Feb, 2025 |
| J. Christopher Naftzger | General Counsel And Cco | 140,544 | 0 | 19 Feb, 2025 |
| Elizabeth Howard | Evp, Gc, Compliance | 86,024 | 0 | 03 Feb, 2023 |
| Tuan Nguyen | Chief Financial Officer | 73,500 | 0 | 02 Feb, 2026 |
| Lindsay Androski | President And Ceo | 28,000 | 0 | 02 Feb, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 02 Feb, 2026 | Tuan Nguyen | Common Shares | A | 73,500 | $0.00 | 73,500 | D | A |
| 02 Feb, 2026 | Lindsay Androski | Common Shares | A | 28,000 | $0.00 | 28,000 | D | A |
| 02 Feb, 2026 | Lindsay Androski | Stock Option (Right to Buy) | A | 71,700 | $0.00 | 71,700 | D | A |
| 02 Feb, 2026 | Tuan Nguyen | Stock Option (Right to Buy) | A | 188,400 | $0.00 | 188,400 | D | A |
| 04 Aug, 2025 | Roger Sawhney | Stock Option (Right to Buy) | A | 157,600 | $0.00 | 157,600 | D | A |
| 31 Mar, 2025 | Tuan Nguyen | Stock Option (Right to Buy) | A | 750,000 | $0.00 | 750,000 | D | A |
| 31 Mar, 2025 | Tuan Nguyen | Stock Option (Right to Buy) | A | 750,000 | $0.00 | 750,000 | D | A |
| 18 Mar, 2025 | Lindsay Androski | Stock Option (Right to Buy) | A | 310,422 | $0.00 | 310,422 | D | A |
| 18 Mar, 2025 | Robert A Beardsley | Stock Option (Right to Buy) | A | 157,600 | $0.00 | 157,600 | D | A |
| 18 Mar, 2025 | Anuj Hasija | Stock Option (Right to Buy) | A | 157,600 | $0.00 | 157,600 | D | A |
| 14 Feb, 2025 | Karen Sims | Common Shares | A | 49,300 | $0.00 | 155,494 | D | A |
| 14 Feb, 2025 | Michael J. Mcelhaugh | Common Shares | A | 177,000 | $0.00 | 1,658,003 | D | A |
| 14 Feb, 2025 | J. Christopher Naftzger | Common Shares | A | 54,300 | $0.00 | 140,544 | D | A |
| 14 Feb, 2025 | J. Christopher Naftzger | Stock Option (Right to Buy) | A | 220,300 | $0.00 | 220,300 | D | A |
| 14 Feb, 2025 | Michael J. Mcelhaugh | Stock Option (Right to Buy) | A | 718,800 | $0.00 | 718,800 | D | A |
| 14 Feb, 2025 | Karen Sims | Stock Option (Right to Buy) | A | 200,300 | $0.00 | 200,300 | D | A |
| 04 Feb, 2025 | J. Christopher Naftzger | Common Shares | D | 11,333 | $3.28 | 86,244 | D | S |
| 04 Feb, 2025 | Michael J. Mcelhaugh | Common Shares | D | 23,790 | $3.28 | 1,481,003 | D | S |
| 04 Feb, 2025 | Karen Sims | Common Shares | D | 19,348 | $3.28 | 106,194 | D | S |
| 23 May, 2024 | Melissa Rewolinski | Stock Option (Right to Buy) | A | 67,000 | $0.00 | 67,000 | D | A |